Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07271667 · ClinicalTrials.gov registry record · Phase 2

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

A Phase 2 study of Chronic Lymphocytic Leukemia and B-cell Malignancies, sponsored by Curis.

Recruiting
Registry status
Phase 2
Development phase
108
Enrollment target
1
Study location

NCT07271667: Recruiting Phase 2 study of Chronic Lymphocytic Leukemia and B-cell Malignancies, sponsored by Curis.

NCT07271667 is a Phase 2 study of Chronic Lymphocytic Leukemia and B-cell Malignancies that is actively recruiting participants, run by Curis. The registered enrollment target is 108 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07271667, a Phase 2 study of Chronic Lymphocytic Leukemia and B-cell Malignancies, is actively recruiting participants, sponsored by Curis.

RECRUITING
Registry status
Phase 2
Development phase
108 participants
Enrollment target
1
Study location

Study Summary

The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.

Conditions Studied

Chronic Lymphocytic Leukemia B-cell Malignancies

Interventions

  • DRUG Zanubrutinib
  • DRUG Emavusertib

Study Locations (1)

Florida

  • Mt Sinai Comprehensive Cancer Center - Miami Beach

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2026-02
Est. Completion 2027-11
Phase Phase 2
Curis

12 total trials

What NCT07271667 shows while recruiting

NCT07271667 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (40% lower).

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.

NCT07271667 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT07271667 about?

NCT07271667 is a clinical study titled "A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies". The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.

What is the current status of trial NCT07271667?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2026-02. Estimated completion is 2027-11.

What conditions does trial NCT07271667 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, B-cell Malignancies.

What interventions are being tested in trial NCT07271667?

The interventions under investigation include: Zanubrutinib (DRUG), Emavusertib (DRUG).

Who is sponsoring clinical trial NCT07271667?

This trial is sponsored by Curis, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07271667 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07271667's enrollment target sits among peer trials

108 60th of 187 higher than 128 of 187 other Chronic Lymphocytic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02703207 · 108 participants · NA

    Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

  • NCT02744677 · 108 participants · NA

    COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

  • NCT02781883 · 108 participants · Phase 2

    Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

  • NCT03848663 · 108 participants · NA

    Visual Remapping to Aid Reading With Field Loss

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

More recruiting context for NCT07271667

Source: ClinicalTrials.gov NCT07271667, the US trial registry maintained by the National Library of Medicine. NCT07271667 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.